Australia's most trusted
source of pharma news
Tuesday, 24 February 2026
Posted 23 February 2026 PM
The first quarter of 2026 has brought a sliver of optimism to industry with the latest pharma sentiment index climbing 12 points - though not enough to quash overwhelming concern about the current state of the sector.
The Biopharma Sentiment Index (BPSI) headline score has jumped from a 'deeply pessimistic' 78 in Q4 2025 to 90. But the good news is tempered by the fact it still falls well short of the 'neutral' baseline of 100 points.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.